InMed Pharmaceuticals Inc. (INM) Earnings History
Net Loss25 years of earnings data (2001–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
InMed Pharmaceuticals Inc. (INM) Earnings Overview
As of June 28, 2026, InMed Pharmaceuticals Inc. (INM) reported trailing twelve-month net income of -$10M, reflecting +58.5% year-over-year growth. The company earned $-2.45 per diluted share over the past four quarters, with a net profit margin of -165.1%.
Looking at the long-term picture, INM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$46,737 in fiscal 2013.
InMed Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including YCBD (-$3M net income, -10.6% margin), ATAI (-$663M net income, -16142.0% margin), MNMD (-$238M net income), INM has room to improve margins relative to the peer group. Compare INM vs YCBD →
INM Earnings vs Peers
Earnings metrics vs comparable public companies
INM Historical Earnings Data (2001–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$8M | -6.3% | -$8M | $-8.36 | -165.1% | -160.2% |
| 2024 | -$8M | +3.4% | -$8M | $-20.14 | -166.9% | -176.9% |
| 2023 | -$8M | +57.3% | -$8M | $-64.92 | -192.2% | -202.6% |
| 2022 | -$19M | -47.0% | -$14M | $-16582.00 | -1707.3% | -1266.0% |
| 2021 | -$13M | -41.5% | -$12M | $-938.91 | - | - |
| 2020 | -$9M | +10.7% | -$9M | $-1161.21 | - | - |
| 2019 | -$10M | -49.2% | -$10M | $-1264.97 | - | - |
| 2018 | -$7M | -95.0% | -$7M | $-1032.30 | - | - |
| 2017 | -$3M | -87.2% | -$3M | $-810.55 | - | - |
| 2016 | -$2M | +46.9% | -$2M | $-643.57 | - | - |
| 2015 | -$3M | -200.1% | -$3M | $-1591.26 | - | - |
| 2014 | -$1M | -2365.2% | -$1M | $-659.66 | - | - |
| 2013 | $-46,737 | +75.4% | $-49,186 | $-25.16 | - | - |
| 2012 | $-189,915 | +41.6% | $-168,719 | $-168.44 | - | - |
| 2011 | $-325,466 | +2.8% | $-387,556 | $-318.24 | -820.7% | -977.2% |
| 2010 | $-334,787 | +68.4% | $-411,402 | $-1492.39 | -421.3% | -517.7% |
| 2009 | -$1M | -14.9% | $-776,998 | $-492.41 | -629.3% | -461.3% |
| 2008 | $-922,260 | +50.8% | -$1M | $-496.33 | -147.9% | -203.7% |
| 2007 | -$2M | -47.3% | -$1M | $-930.18 | -227.0% | -138.4% |
| 2006 | -$1M | +54.2% | -$1M | $-1108.33 | -46.1% | -42.6% |
| 2005 | -$3M | -82.8% | -$2M | $-4236.29 | -65.6% | -47.0% |
| 2004 | -$2M | -23.5% | -$1M | $-372.20 | -72.6% | -59.4% |
| 2003 | -$1M | +54.6% | -$1M | $-301.31 | -662.9% | -690.0% |
| 2002 | -$3M | +36.5% | -$3M | $-664.14 | -19696.6% | -19989.6% |
| 2001 | -$4M | - | -$4M | $-1045.33 | -174800.3% | -174165.2% |
Download Data
Export INM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INM — Frequently Asked Questions
Quick answers to the most common questions about buying INM stock.
What is INM earnings per share (EPS)?
INM trailing twelve-month (TTM) diluted EPS is $-2.45, reflecting +58.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2001 to 2025 is available in the table on this page.
What is InMed Pharmaceuticals Inc.'s net income?
InMed Pharmaceuticals Inc. (INM) trailing twelve-month net income is $-10M as of 2025. Earnings grew +58.5% year-over-year.
Is INM profitable?
INM is not currently profitable on a TTM basis, reporting a net loss of $-10M. Net margin is -165.1%. Investors should monitor for a return to profitability.
What is INM's earnings growth rate?
INM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2001 to 2025.
What are INM's profit margins?
InMed Pharmaceuticals Inc. net profit margin is -165.1%, operating margin is -160.2%, and gross margin is +34.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -52.8%.
Is INM growing earnings?
Yes, INM earnings are accelerating — EPS growth of +58.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-10M. Earnings momentum is strengthening.
What was INM's best earnings year?
InMed Pharmaceuticals Inc.'s highest annual net income on record is $-46737.00, achieved in fiscal year 2013. Earnings history on this page spans 2001 to 2025 and includes all annual and quarterly figures.
What were INM's earnings last quarter?
INM's most recent reported quarter was Q3 2026. Net income was $-3M with diluted EPS of $-0.73. For a full breakdown of all quarters, see the quarterly earnings table on this page.